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Summary
Objective: To examine the effect of an oral preparation of avocado and soya unsaponifiables (ASU) on the development of joint pathology
in an ovine model of osteoarthritis (OA), using computer-assisted histomorphometric methods.
Design: OA was induced in ovine knee joints by bilateral lateral meniscectomy (N=32). ASU (900 mg/weekday) was given orally to half the
group (MenX+ASU), the remainder receiving placebo (MenX). Sixteen animals were used as non-operated controls (NOC). At 3 and 6
months post-meniscectomy, histological sections from the medial and lateral femoral condyles (MFC, LFC), tibial plateaux (MTP, LTP) and
trochlear groove (TG) were prepared from all joints. Sections were scored using traditional histopathological scales, and computerized image
analysis, measuring total cartilage area, uncalcified cartilage (UCC) and subchondral bone plate (SCP) thickness, and intensity of articular
cartilage toluidine blue staining (mean greyscale intensity, black=255) as an index of proteoglycan (PG) content.
Results: Computerized image analysis showed significant histological differences not detectable by traditional scoring methods. ASU-treated
animals at 6 months showed reduced loss of toluidine blue stain in the MTP (P=0.015) and LTP (P=0.001), and significantly greater staining
in the TG than either placebo or NOC groups (P=0.011). UCC thickness increased after meniscectomy, but tended to be highest in
ASU-treated animals, significantly so in the middle zone of the LFC (MenX+ASU: 1.03±0.21mm vs MenX: 0.79±0.14 mm, P=0.018; NOC:
0.77±0.17 mm). Lateral compartment SCP thickness increased post-meniscectomy but was increased significantly less in the inner zone of
the LTP in ASU-treated sheep (MenX+ASU: 1.37±0.23 mm vs MenX: 1.68±0.28 mm, P=0.033; NOC=1.22±0.33 mm).
Conclusions: In this model ASU treatment following meniscectomy appeared to confer a subtle but statistically significant protective effect on
articular cartilage. Although the drug failed to prevent focal cartilage lesions, characteristic of this model, histomorphometric analysis
demonstrated greater PG content and UCC thickness in adjacent joint regions of ASU-treated animals. In addition, a statistically significant
reduction of subchondral bone sclerosis was noted in the LTP region of the drug-treated group. An anabolic effect on chondrocytes, resulting
in the stimulation of matrix production in regions distant to the insult, was also suggested by the data. These findings support other studies
which have proposed that ASU may exhibit disease-modifying anti-OA activity. © 2000 OsteoArthritis Research Society International
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Articular cartilage (AC) consists of chondrocytes sparsely
embedded within an abundant extracellular matrix, com-
posed essentially of water, proteoglycans (PGs), collagens,
and non-collagenous proteins. It is the swelling pressure of
the partially hydrated proteoglycan gel, restrained by the
inextensible collagen network, that gives cartilage its resili-
ence and unique load-bearing properties. While the fibrillar
collagens of adult cartilage have long half-lives1 the PGs
are constantly being turned over, the net concentration
being determined by the dynamic balance between their
synthesis and degradation. In osteoarthritic joints however,
this equilibrium is disturbed in favour of PG catabolism,
their loss from the AC extracellular matrix leading to
deterioration in its biomechanical properties.2,3 Cytokines404originating from the inflamed synovial membrane, as well
as the chondrocytes themselves, can inhibit PG synthesis
and promote their catabolism.4,5 Especially important in
this regard is interleukin-1 (IL-1) which, even at very
low concentrations, will inhibit synthesis of PG by
chondrocytes4–6 and stimulate the production of enzymes
such as matrix metalloproteinases1,7 as well as oxygen-
derived free radicals including nitric oxide,8 which can
degrade the matrix and cause chondrocyte apoptosis.9 In
the early hypertrophic stages of experimental osteoarthritis
(OA) increased chondrocyte biosynthetic activity usually
precedes the inhibition of synthesis or degradation of PGs,
resulting in a period of increased PG concentration in the
matrix.10–12 This early response is generally coupled with
minor damage to the collagen network, particularly in the
superficial region, resulting in overhydration of PGs and
thickening of AC.11,12
Management of OA in the past has primarily focused on
the relief of symptoms, using agents such as analgesics
and non-steroidal antiinflammatory drugs (NSAIDs). Such
an approach has been criticized for failing to prevent
continued articular cartilage degeneration, and in the caseAddress correspondence to: Associate Professor Peter Ghosh,
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OVINE MENISCECTOMY MODEL
Forty-eight mature (3-year-old) Merino wethers were
obtained from a single source. Animals were selected for
uniformity of size, conformation, soundness of health and
absence of lameness. Animals were assigned randomly to
one of six treatments groups. In four of the groups, bilateral
lateral meniscectomy was performed as described,29 by a
single surgeon. Surgery on both left and right joints
was performed within a single anaesthetic procedure.
Electrocautery was used and careful attention was
paid to intraoperative haemostasis. All animals received
cefazolin, flunixin, and fentanyl patches (Durogesic,
Janssen, Belgium) perioperatively. All animal procedures
were approved by the Murdoch University Animal Ethics
Committee.
Following a brief recovery period, sheep were main-
tained on irrigated pasture (supplemented with lupin grain).
From approximately 1 month post-operatively, meniscect-
omized groups were given orally administered capsules of
ASU (Piascledine 300®) (900 mg/weekday) or placebo
(paraffin oil) both provided by Pharmascience (Laboratoires
Pharmascience, Courbevoie, France). This dose, higher
than the usual daily human dose, was used to compensatefor the weekday only administration protocol and the possi-
bility of partial degradation of the compound in the rumen.
Body weights were recorded at approximately monthly
intervals. Treatment groups were therefore: meniscectomy
plus ASU (MenX+ASU), meniscectomy plus placebo
(MenX), or non-operated control (NOC). Eight sheep of
each treatment type were killed at approximately 3 and 6
months post-operatively (p.o.) (except the 6-month MenX
group, which contained only seven animals, due to death of
one animal from causes unrelated to the experimental
protocol).GROSS PATHOLOGY
Joints were immediately dissected and processed for
histology. At 6 months, colour slide photographs were taken
of the joints and later used to score gross pathology
(cartilage integrity, score 0–4: 0=normal, 1=roughened,
2=fibrillated/fissured, 3=erosions <5 mm, 4=erosions
>5 mm; osteophyte development, score 0–3: 0=none,
1=mild, 2=moderate, 3=marked osteophyte formation).HISTOLOGICAL METHODS
Histological sections were prepared from five joint
regions of one randomly-selected hind limb: medial and
lateral femoral condyles (MFC, LFC), medial and lateral
tibial plateaux (MTP, LTP), and (6 months p.o. only) troch-
lear groove (TG). Slices (approximately 3 mm thick) were
taken from each region by bandsaw cuts in the medio-
lateral plane, perpendicular to the articular surface, by a
single operator using a standard protocol. Cuts were posi-
tioned in the femoral condyles at the point of tibial contact
in normal stance, and in the tibial plateaux at the level of
the intercondylar eminences. Slices were fixed in 10%
neutral buffered formalin for 48 h, then decalcified in 10%
formic acid/5% formaldehyde for 7 days. Specimens were
then washed, dehydrated in increasing concentrations of
ethanol (70–100%), and double-embedded in methyl
benzoate/celloidin then paraffin wax. Four micrometre sec-
tions were cut on a rotary microtome and adhered to
Superfrost Plus glass slides (Menzel Gla¨ser, U.S.A.) for
toluidine blue and Masson’s trichrome staining.
Toluidine blue staining was performed under constant
conditions. Sections were deparaffinized, dehydrated then
equilibrated in 70% alcohol for 15 min, stained in 0.04%
toluidine blue O/0.1 M sodium acetate buffer, pH 4.0
(10 min) and 0.1% fast green FCF (2 min), dehydrated in
isopropanol then xylene, and cover-slipped.HISTOPATHOLOGICAL GRADING
Semi-quantitative histopathological grading was per-
formed according to a modified Mankin’s grading sys-
tem.28,33,34 In one toluidine blue-stained section from each
of the five joint regions, four zones were scored:28 outer
(abaxial) margin, outer perilesional zone, lesional zone (or
spatially equivalent zone in controls), and inner perilesional
zone. Scoring was done by a single observer, according to
a five-point scale (Table I), and a mean aggregate score
determined as the average of these four values (total
possible score=26).HISTOMORPHOMETRIC IMAGE ANALYSIS
Computer-assisted histomorphometric analysis was con-
ducted in a manner similar to that described by Shimizuof certain NSAIDs, exacerbating the process by inhibiting
PG synthesis.13,14 Identifying agents which are capable of
preventing, slowing, or reversing the structural and patho-
logical alterations which occur in osteoarthritic joints is an
important research objective. Evaluation of such agents is
difficult in clinical trials, due to the slow progression of OA
in humans and the challenge of assessing joint changes
by non-invasive methods.15,16 The use of animal models
permits the timing of onset to be known, producing a
homogeneous, reliable model of the OA process for the
evaluation of disease-modifying therapies.17–18
ASU is a new antiarthritic agent derived from unsaponi-
fiable residues of avocado and soya oils, mixed in the ratio
of 1:2 respectively. Avocado/soya unsaponifiables have
recently been shown in various in vitro systems to partially
reverse the effects of IL-1 on cultured chondrocytes,
stimulating collagen synthesis and inhibiting the production
of matrix metalloproteases, IL-6, IL-8 and PGE2.19–22 A
similar effect has also been demonstrated in rheumatoid
synoviocytes.20,21 Boumediene et al. recently reported that
ASU enhanced the expression of transforming growth
factor- (TGF) in cultured articular chondrocytes, provid-
ing the first clues as to its possible mode of action.23 The
active ingredients of the plant extract are unknown, but
synergism between the avocado and soya components,
and their relative ratios, appears to be important.19,24 The
only published animal study found oral ASU significantly
prevented the occurrence of cartilage lesions in a rabbit
post-contusive model.25 While its symptomatic efficacy
has been demonstrated recently in double-blind, placebo-
controlled prospective clinical trials in patients with OA,24,26
including evidence of reduced joint space narrowing,27 its
ability to also protect the articular cartilage of osteoarthritic
joints in vivo remains to be established.
The purpose of the present study was to examine the
effect of ASU on the histological progression of joint
changes in meniscectomized sheep, a model which pro-
duces morphological and biochemical changes very similar
to those described for early human OA.13,17,18,28–32
406 M. A. Cake et al.: ASU modifies cartilage pathologyet al.35 Sections were scanned directly using a slide
scanner (Microtek Slidescanner 35t plus; Model No. PTS-
1950), and acquired at 400 dpi resolution using standard
graphics software (Adobe Photoshop v3.0, Adobe Sys-
tems, U.S.A.). Stored image files were analysed using
image analysis software (ImagePro Plus v3.0.1; Media
Cybernetics, U.S.A.) on a personal computer (Power
Macintosh 7600/200). Spatial calibration was performed
using a 10×10 mm high precision graticule, and the inten-
sity scale was calibrated to give a positive linear response
to increasing optical density (black=255).
Staining intensity and total area (mm2) of articular carti-
lage were determined in one toluidine blue-stained section
from each joint region, at 3 and 6 months. The intensity of
toluidine blue staining, an index of proteoglycan content,36
was measured as the mean pixel optical density after
conversion from RGB colour to greyscale. Uncalcified car-
tilage and subchondral bone plate thickness (mm) were
determined from Masson’s trichrome-stained sections at
6 months only, using a radial thickness algorithm within the
software to generate the mean thickness measurements
between lines delimiting the cartilage surface, the most
advanced tidemark, and the limit of cortical subchondral
bone (intertrabecular spaces <500 m), after dividing the
cartilage visually into thirds, such that each arc segment
comprised approximately one-third of the total arc length,
termed outer (marginal), middle, and inner zones (Fig. 1).
The middle zone, being the point of weight-bearing in the
absence of a meniscus, included the usual point of erosion
in the lateral compartment of meniscectomized animals.
Reproducibility of this method has been assessed pre-
viously (unpublished data) and found to be high (mean
variation of repeated analyses ±5%), especially for meanstaining intensity measurements (±2%). As the degree of
toluidine blue staining might be expected to be influenced
by variables such as staining time, all sections were
sectioned and stained using stringent protocols, to
minimize this source of variability.Table I
Grading method used to derive histopathological scores (from Little et al.)28
I Structure 0 Normal
1 Slight surface irregularities
2 Moderate surface irregularities
3 Severe surface irregularities
4 Clefts/fissures into transitional zone (one-third depth)
5 Clefts/fissures into radial zone (two-thirds depth)
6 Clefts/fissures into calcified zone (full depth)
7 Fibrillation and/or erosion to transitional zone (one-third depth)
8 Fibrillation and/or erosion to radial zone (two-thirds depth)
9 Fibrillation and/or erosion to calcified zone (full depth)
10 Fibrillation and/or erosion to subchondral bone
II Cellularity 0 Normal
1 Increase or slight decrease
2 Moderate decrease
3 Severe decrease
4 No cells present
III Chondrocyte cloning 0 Normal
1 Several doublets
2 Many doublets
3 Doublets and triplets
4 Multiple cell nests
IV Territorial toluidine blue staining 0 Normal




V Interterritorial toluidine blue staining 0 Normal
1 Loss of staining to tangential zone (one-third depth)
2 Loss of staining to transitional zone (two-thirds depth)
3 Loss of staining to radial zone (full depth)
4 No stainingFig. 1. Cross-sectional view of the knee joint, showing the division
of each region into three equal sections termed the inner, middle,
and outer zones. In each zone, the thickness of the uncalcified
cartilage (UCC) and subchondral bone (SCB) was determined
using computer-assisted image analysis.STATISTICAL ANALYSIS
Statistical comparisons were generated using specialist
software (Statview 5.0, SAS Institute Inc., U.S.A.), perform-
ing one-way analysis of variance (ANOVA) to analyse
variance across treatment groups, and Fisher’s analysis of
least significant difference (Fisher’s PLSD) to compare
Osteoarthritis and Cartilage Vol. 8 No. 6 407treatment group means, except where indicated. A signifi-
cance level of P=0.05 was used throughout. The medial
compartment of the joint was found to be significantly
affected by lateral meniscectomy, preventing the use of the
medial compartment as an internal control.ResultsBODY WEIGHT
There was no significant difference in body weights
between the three groups before the trial commenced
(Table II). Animals were in moderately lean body condition.
After surgery, mean body weights of meniscectomized
animals were significantly below those of non-operated
control animals. Mean body weights of animals receiving
placebo capsules were consistently lower than those of
animals receiving ASU, significantly so at 5–6 months
post-operatively (unpaired t-test, P<0.05).GROSS PATHOLOGY
Meniscectomized joints showed gross pathological
changes comparable with early human OA, with articular
cartilage erosion in the lateral compartment (milder
changes in the medial compartment), and moderate–
marked osteophyte development. In control animals, gross
changes were restricted to occasional cartilage roughen-
ing, and/or slight osteophyte formation, in the medial com-
partment. Joints of animals treated with ASU tended to
have lower cartilage scores than nontreated (Table II), in
the lateral femoral condyle (2.81 vs 3.07, maximum=4) and
lateral tibial plateau (2.25 vs 2.64). However, these differ-
ences were not statistically significant. Osteophyte values
were similarly high in both groups.HISTOPATHOLOGICAL SCORES
Mean histopathological scores were higher in meniscec-
tomized animals compared to those of NOC. This differ-
ence was significant only in the lateral compartment at
3 months, but in all regions at 6 months p.o. There were no
significant differences between aggregate scores of ASU-
treated animals and those of the placebo group at 3 or6 months. MenX+ASU animals showed a tendency for
lower scores than MenX in the LFC at 6 months, which
approached significance (8.0±0.4 vs 9.0±0.2, P=0.0504;
NOC=3.1±0.3; maximum=26) (Table II).IMAGE ANALYSISCartilage area
Meniscectomized joints had significantly greater total
cartilage area than those of control animals in all regions.
This was primarily attributable to significant increases in the
inner and outer cartilage zones. The middle zone showed
similar trends, except in the LFC and LTP where erosion of
the cartilage surface reduced this increase. In all regions
(except the tibial plateaux at 3 months p.o.), MenX+ASU
tended to have slightly greater total cartilage area than
MenX animals; however, this tendency was not significant
in any region.Intensity of toluidine blue staining
At 3 months p.o., the mean intensity of cartilage toluidine
blue staining tended to increase in the medial compart-
ment, but decrease in the lateral compartment, primarily
due to loss of stain in the area of central erosion. At
6 months p.o., loss of toluidine blue stain predominated,
except in the trochlear groove. MenX+ASU animals
showed either a greater increase or decreased loss of stain
relative to MenX in all regions, significant in the MTP (90±9
vs 78±11, P=0.015), LTP (81±4 vs 67±9, P=0.001), and
TG (104±9 vs 93±7, P=0.023; NOC=89±6, P=0.011) at
6 months p.o. (Table III).Table II
Body weights, gross pathology, and histopathological scores (mean±S.D.) at time points indicated, in control
(NOC), meniscectomized (MenX), and ASU-treated meniscectomized (MenX+ASU) animals
Treatment group NOC MenX+ASU MenX
Weight (kg): Initial 46.9±4.7 49.5±4.0 47.7±5.1
3 months 52.6±5.3 50.3±5.6 48.1±3.8*
6 months 62.7±8.6 61.2±2.6† 56.2±2.5a
Gross pathology score,b 6 months
Cartilage fibrillation (max=32) 1.3±1.3 12.4±2.1* 13.7±4.2*
Osteophyte formation (max=24) 0.9±1.1 12.8±2.7* 12.9±3.7*
Histopathological Score,c 6 months
LFCd (max=26) 3.1±0.3(3.7) 8.0±0.4*e(14.5) 9.1±0.2*(17.6)
LTPd (max=26) 4.4±0.6(5.9) 9.0±0.7*(15.3) 9.0±0.5*(16.4)
*Significantly different from relevant NOC value, P<0.05.
†MenX+ASU significantly different from relevant MenX value, P<0.05.
a: P=0.076 (MenX vs NOC); b: sum of four joint regions assessed, both knees, at six months; c: mean of four
zones assessed, one knee only—figure in parentheses is mean for lesion zone alone; d: LFC=lateral femoral
condyle; LTP=lateral tibial plateau; e: P=0.0504 (MenX+ASU vs MenX).UCC and SCP thickness
Mean uncalcified cartilage thickness tended to increase
at 6 months following meniscectomy. Thickness tended to
be higher in MenX+ASU than MenX, especially in the
middle (lesion) zone. In the middle zone of the LFC,
MenX+ASU UCC thickness was significantly greater than
MenX (P=0.0181) or NOC (Fig. 2). In the middle zone of
the LTP, MenX was below both NOC and MenX+ASU
(P=0.0506) values. Subchondral plate thickness tended to
408 M. A. Cake et al.: ASU modifies cartilage pathologyincrease in the lateral compartment following meniscec-
tomy. This increase was greatest in the outer zone, but was
significant in all zones. In the inner zone of the LTP,significantly lower SCP thickness was found in MenX+ASU
compared with MenX animals (P=0.0492) (Fig. 3).Table III
Intensity of toluidine blue staining (mean greyscale pixel intensity, mean±S.D., black=255) in control (NOC),
meniscectomized (MenX), and ASU-treated meniscectomized (MenX+ASU) animals
Joint region 3 months 6 months
NOC MenX+ASU MenX NOC MenX+ASU MenX
MFC 99±9 108±10 102±4 88±19 91±11 88±7
LFC 102±14 97±9 89±11 93±14 86±8 82±16*
(LFC—Middle zone) (106±18) (71±14)* (72±22)* (96±16) (78±16)* (71±15)*
MTP 90±14 104±10* 101±5* 98±7 90±9† 78±11*
LTP 93±13 88±10 81±17 92±7 81±4*† 67±9*
(LTP—Middle zone) (98±15) (63±13)* (71±21)* (95±8) (74±8)*† (53±22)*
TG — — — 89±6 104±9*† 92±7
MFC: medial femoral condyle; LFC: lateral femoral condyle; MTP: medial tibial plateau; LTP: lateral tibial
plateau; TG: trochlear groove. Figures in parentheses are mean of middle zone only.
*Significantly different from relevant NOC value, P<0.05.
†MenX+ASU significantly different from relevant MenX value, P<0.05.Fig. 2. Mean uncalcified cartilage thickness by zone, in the lateral
femoral condyle (a) and lateral tibial plateau (b). NOC;
MenX+ASU; MenX after 6 months. *=Significantly different
from relevant NOC, P<0.05; **=MenX+ASU significantly different
from MenX, P<0.05.Fig. 3. Mean subchondral plate thickness in the lateral tibial
plateau, graphed as % of zone NOC mean. NOC;
MenX+ASU; MenX after 6 months. *=Significantly different
from relevant NOC, P<0.05; **=MenX+ASU significantly different
from MenX, P<0.05.Discussion
Traditionally, histological analysis of cartilage pathology
has been qualitative. Whilst histological grading systems
have been used, such as that developed by Mankin,34
these are at best semi-quantitative, subjective, and prone
to interuser variability. Recent applications of image analy-
sis systems to quantitative analysis of cartilage changes
demonstrate the potential and acceptance of this
technology.35,37–40 The present study utilized a similar
method to that recently published by Shimizu et al.35 who
found that determination of cartilage staining intensity and
area by computerized image analysis allowed a reliable
and precise evaluation of cartilage deterioration in a rabbit
model of OA.
Results obtained in this study have confirmed the advan-
tages of computerized, quantitative methodologies for his-
tomorphometric assessment of joint changes in arthritis.
Scores obtained by gross visual assessment and a
Osteoarthritis and Cartilage Vol. 8 No. 6 409published histopathological scoring method28,33 failed to
demonstrate any significant effect of ASU treatment. How-
ever, results obtained by image analysis revealed subtle
though statistically significant effects of the drug, in
maintaining articular cartilage proteoglycan content and
thickness, and modifying subchondral sclerosis.
The increase in cartilage area and thickness seen follow-
ing meniscectomy may be the result of cartilage swelling
(overhydration following disruption of the collagen net-
work), marginal osteochondral remodelling, and/or hyper-
trophic matrix production.2,12 In this study, cartilage
thickness increased post-meniscectomy in parallel with
cartilage area in most regions, suggesting that a true
increase in articular cartilage thickness, as well as remod-
elling and marginal osteophyte formation, was responsible.
However, cartilage erosion occurred simultaneously, par-
tially reversing this increase and giving meniscectomized
animals mean UCC thickness values in the eroded middle
zone similar to those of controls. The tendency for greater
cartilage thickness observed in the middle cartilage zone of
ASU-treated animals, statistically significant in the LFC
[Fig. 2(a)], is therefore difficult to interpret, but may be a
result of reduced cartilage erosion, and/or increased matrix
production, in the presence of a disrupted collagen net-
work. However, other causes, such as increased cartilage
hydration, cannot be excluded by histomorphometric data
alone.
Quantitation of toluidine blue staining provides further
evidence of partial preservation of articular cartilage integ-
rity by ASU following cartilage insult. Loss of toluidine blue
staining was significantly reduced by ASU treatment in both
tibial plateaux at 6 months p.o. In the trochlear groove at
6 months p.o., toluidine blue staining of MenX+ASU ani-
mals was significantly greater than either MenX or NOC
animals. Again, the tendency for increased (or reduced loss
of) cartilage proteoglycan content in ASU-treated animals
may be the result of decreased catabolism and/or
increased anabolism. It was recently suggested that many
of the actions of ASU may be mediated by an increase in
expression of TGF,23 a potent stimulator of chondrocyte
matrix production and antagonist of the deleterious effects
of IL-1.41–45 The results of this trial appear consistent with
such a mechanism of action.
Subchondral bone plate changes reflected altered joint
mechanics resulting from meniscectomy, in that thickness
decreased in the outer zone of the medial compartment
(reduced weight bearing), and increased in the lateral
compartment, especially in zones previously protected by
the meniscus. Subchondral bone sclerosis is an early event
in OA and may contribute to its pathogenesis.46,47 Signifi-
cantly reduced subchondral sclerosis in the inner zone of
the LTP in ASU-treated animals suggests modification of
OA-stimulated subchondral events by this drug. However,
as SCP thickness changes were more pronounced in other
zones, in which the drug showed no effect, the importance
of this effect is unknown.
Previously reported histomorphometric studies have util-
ized the rabbit anterior cruciate ligament transection
model.36,39 In this rapidly progressive model, severe carti-
lage erosion and disruption predominate. In the present
ovine model, histopathological changes induced are com-
paratively mild, and cartilage erosion is relatively focal.
Therefore, histomorphometric methods which quantitate
changes over the entire articular cartilage area may be
more sensitive to surrounding compensatory and hyper-
trophic events, complicating interpretation of results. The
division of the cartilage area into inner, middle and outerzones aided quantitation of focal events such as cartilage
erosion.
Little clinical data was collated in this trial. However,
body weight changes provide possible clinical evidence for
an improvement of animal well-being by ASU treatment.
Decreased weight gain of meniscectomized animals is
likely to be a result of post-surgical stress and subclinical
lameness (affecting grazing behaviour, therefore lowering
food intake). This effect appears to be lessened in animals
treated with ASU, though a direct effect of the drug on
weight gain cannot be ruled out from the data. It is also
possible that ASU may confer analgesic properties inde-
pendent of any chondroprotective effects. Patient non-
steroidal antiinflammatory drug usage was evaluated as
the primary efficacy criteria in one placebo-controlled
clinical trial,26 and was found to be significantly reduced by
ASU treatment. However, an increase in exercise has been
shown to exacerbate the cartilage degeneration seen in the
similar ovine medial meniscectomy model.30,32 Any anal-
gesic effect attributable to ASU in this trial would therefore
be expected to have lessened the beneficial effects seen
on the progression of osteoarthritic lesions.
In conclusion, the present trial provides evidence sup-
porting published in vitro studies, suggesting ASU are
capable of stimulating matrix production and reducing the
deleterious effects of IL1 on articular chondrocyte
metabolism,19–22 possibly via enhanced expression of
TGF.23 First, administration of ASU had an evident effect
on articular cartilage proteoglycan content, partially pre-
venting loss of PG following meniscectomy (statistically
significant in the tibial plateaux at 6 months), and exagger-
ating the compensatory increase in proteoglycan produc-
tion in areas distant to the insult, such as the trochlear
groove. Second, ASU-treated animals demonstrated
greater UCC thickness than placebo-treated animals, in
the eroded middle zone of the meniscectomized lateral
compartment. The authors interpret this as represent-
ing reduced erosion of damaged cartilage, suggesting
enhanced cartilage integrity following injury. However, this
effect was statistically significant only in the lateral femoral
condyle, and may be explained by other mechanisms.
Third, a significant effect on SCP thickness in the LTP may
be evidence for modification of subchondral sclerosis by
ASU treatment. These findings support previous studies
suggesting ASU may exhibit disease-modifying activity in
osteoarthritic conditions.Acknowledgments
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